Esperion Highlights New Exploratory Data From CLEAR Outcomes Trial Highlighting Value Of NEXLETOL In Oral Featured Science Session And Multiple Poster Presentations At AHA Scientific Sessions 2024; Exploratory Analysis Reports Patients With PAD Who Took Bempedoic Acid Were 36% Less Likely To Experience A Major Adverse Limb Event Compared To Placebo
– An Exploratory Analysis Reports Patients with PAD Who Took Bempedoic Acid Were 36% Less Likely to Experience a Major Adverse Limb Event Compared to Placebo –
ANN ARBOR, Mich., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the presentation of an analysis from the CLEAR Outcomes study focused on patients with Peripheral Artery Disease (PAD) who were unable or unwilling to take statin medications. These data were presented today in an oral featured science presentation at the 2024 American Heart Association (AHA) Scientific Sessions, which took place from November 16-18, 2024, in Chicago, IL. Additionally, two exploratory analyses from the CLEAR Outcomes trial and a real-world analysis of bempedoic acid usage were presented at the conference.
